Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Wahl

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Frontiers in Endocrinology|March 3, 2020
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer CellsAnna R Michmerhuizen, Benjamin Chandler, Eric Olsen, et al.
Nature Biotechnology|May 12, 2010
A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal functionJosef S Ozer, Frank Dieterle, Sean Troth, et al.
Cancer Cell|December 1, 2023
A road map for the treatment of pediatric diffuse midline gliomaCarl Koschmann, Wajd N Al-Holou, Marta M Alonso, et al.
Cancer Discovery|August 16, 2023
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic PathwaysSriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, et al.
Cancer Discovery|March 3, 2025
Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic PathwaysSriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Frontiers in Endocrinology|March 3, 2020
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer CellsAnna R Michmerhuizen, Benjamin Chandler, Eric Olsen, et al.
Nature Biotechnology|May 12, 2010
A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal functionJosef S Ozer, Frank Dieterle, Sean Troth, et al.
Cancer Cell|December 1, 2023
A road map for the treatment of pediatric diffuse midline gliomaCarl Koschmann, Wajd N Al-Holou, Marta M Alonso, et al.
Cancer Discovery|August 16, 2023
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic PathwaysSriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, et al.
Cancer Discovery|March 3, 2025
Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic PathwaysSriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, et al.
Pageof 2